Context Therapeutics Inc. (CNTX) Stock Score, Valuation & Financial Research

Context Therapeutics Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CNTX

Context Therapeutics Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.32. These figures are a research snapshot, not a buy or sell recommendation.

What Context Therapeutics Inc. does

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Context Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule and monoclonal antibody therapies for hormone-driven and other solid tumors. The company does not currently generate revenue from product sales and relies on capital raises and potential future licensing or collaboration agreements to fund its research and development activities.

Products and services

  • The company's primary product candidates include CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 T-cell engaging bispecific antibody, both currently in clinical or preclinical development stages.

Customer types

Healthcare providers and clinical research institutions.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials and drug candidates; specific supplier names are not disclosed. Source

Business strengths to evaluate

  • Focused pipeline of bispecific antibody candidates targeting high-need solid tumors Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Reliance on a limited number of employees and consultants Source
  • Dependence on third-party contract manufacturing organizations for clinical supply Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CNTX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.32
Market capitalization:
29.57M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -45.96M
Free cash flow:
USD -26.42M
Cash:
USD 42.99M
Total debt:
USD 244.99K
EPS:
USD -0.48

What stands out

  • Free cash flow is USD -26.42M, negative for the stored period.
  • The balance sheet shows USD 42.99M of cash versus USD 244.99K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 42.75M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CNTX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can CNTX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is CNTX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for CNTX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of CNTX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research CNTX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.